|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 October 2000, Vol. 96, No. 8, pp. 2703-2711
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Analysis of engraftment, graft-versus-host disease, and immune
recovery following unrelated donor cord blood transplantation
Blythe G. Thomson,
Kent A. Robertson,
Darla Gowan,
Doug Heilman,
Hal E. Broxmeyer,
David Emanuel,
Patricia Kotylo,
Zacharie Brahmi, and
Franklin
O. Smith
From the Stem Cell Transplantation Program,
Department of Pediatric Hematology/ Oncology; Herman B. Wells Center
for Pediatric Research; Department of Biostatistics; Department of
Microbiology and Immunology; Department of Medicine; Department of
Pathology; and Walther Oncology Center, Indiana University School of
Medicine; and the Walther Cancer Institute, Indianapolis, IN.
Unrelated cord blood (UCB) is being used as a source of alternative
hematopoietic stem cells for transplantation with increasing frequency.
From November 1994 to February 1999, 30 UCB transplant procedures were
performed for both malignant and nonmalignant diseases in 27 children,
aged 0.4 to 17.1 years. Patients received either HLA-matched (n = 3)
or 1- or 2-antigen-mismatched (n = 27) UCB following 1 of 2 standardized preparative and graft-versus-host disease regimens
(hyperfractionated total body irradiation, cyclophosphamide, and
antithymocyte globulin [ATG] with cyclosporine A and methotrexate; or
busulfan, melphalan, and ATG with cyclosporine A and prednisone). The
median time to neutrophil and platelet engraftment was 27 days (12-60 days) and 75 days (33-158 days) posttransplantation, respectively. No
correlation was noted between neutrophil and platelet engraftment and
nucleated cells per kilogram, CD34+ cells per kilogram
infused, or cytomegalovirus status of recipient. The cumulative
probability of acute grade 2 or greater graft-versus-host disease
(GVHD) was 37.2%, and of grade 3 or greater GVHD was 8.8%. No
patients developed chronic GVHD. CD4, CD19, and natural killer cell
recovery was achieved at a median of 12, 6, and 2 months, respectively.
CD8 recovery was delayed at a median of 9 months. Normal mitogen
response was achieved at 6 to 9 months. The probability of survival,
disease-free survival, and event-free survival at 1 year was 52.3%
(34.1%-70.5%), 54.7% (34.5%-74.9%) and 49.6% (29.9%-69.4%),
respectively. This series of 30 UCB transplants suggests that although
CD8 cell recovery is delayed, the pattern of immune reconstitution with
UCB is similar to that reported for other stem cell sources.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. G. Brunstein, J. E. Wagner, D. J. Weisdorf, S. Cooley, H. Noreen, J. N. Barker, T. DeFor, M. R. Verneris, B. R. Blazar, and J. S. Miller
Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity
Blood,
May 28, 2009;
113(22):
5628 - 5634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Vago, B. Forno, M. P. Sormani, R. Crocchiolo, E. Zino, S. Di Terlizzi, M. T. Lupo Stanghellini, B. Mazzi, S. K. Perna, A. Bondanza, et al.
Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation
Blood,
October 15, 2008;
112(8):
3488 - 3499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. V. Komanduri, L. S. St. John, M. de Lima, J. McMannis, S. Rosinski, I. McNiece, S. G. Bryan, I. Kaur, S. Martin, E. D. Wieder, et al.
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing
Blood,
December 15, 2007;
110(13):
4543 - 4551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Iori, W. Arcese, F. Milano, E. Calabrese, G. F. Torelli, W. Barberi, M. G. Mascolo, L. De Felice, M. Screnci, B. Lucarelli, et al.
Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up
Haematologica,
August 1, 2007;
92(8):
1051 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bornstein, A. I. Flores, M. A. Montalban, M. J. del Rey, J. de la Serna, and F. Gilsanz
A Modified Cord Blood Collection Method Achieves Sufficient Cell Levels for Transplantation in Most Adult Patients
Stem Cells,
March 1, 2005;
23(3):
324 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montagna, F. Locatelli, A. Moretta, D. Lisini, C. Previdere, P. Grignani, P. DeStefano, G. Giorgiani, E. Montini, S. Pagani, et al.
T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation
Blood,
June 1, 2004;
103(11):
4322 - 4329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Jiang, C. Van de Ven, P. Satwani, L. V. Baxi, and M. S. Cairo
Differential Gene Expression Patterns by Oligonucleotide Microarray of Basal versus Lipopolysaccharide-Activated Monocytes from Cord Blood versus Adult Peripheral Blood
J. Immunol.,
May 15, 2004;
172(10):
5870 - 5879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Y. Ng, B. van Kessel, H. M. Lokhorst, M. R. M. Baert, C. M. M. van den Burg, A. C. Bloem, and F. J. T. Staal
Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity
J. Leukoc. Biol.,
February 1, 2004;
75(2):
314 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Grewal, J. N. Barker, S. M. Davies, and J. E. Wagner
Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?
Blood,
June 1, 2003;
101(11):
4233 - 4244.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Reed, R. Smith, F. Dekovic, J. Y. Lee, J. D. Saba, E. Trachtenberg, J. Epstein, S. Haaz, M. C. Walters, and B. H. Lubin
Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease
Blood,
January 1, 2003;
101(1):
351 - 357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Chute, A. A. Saini, D. J. Chute, M. R. Wells, W. B. Clark, D. M. Harlan, J. Park, M. K. Stull, C. Civin, and T. A. Davis
Ex vivo culture with human brain endothelial cells increases the SCID-repopulating capacity of adult human bone marrow
Blood,
December 15, 2002;
100(13):
4433 - 4439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Wagner, J. N. Barker, T. E. DeFor, K. S. Baker, B. R. Blazar, C. Eide, A. Goldman, J. Kersey, W. Krivit, M. L. MacMillan, et al.
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
Blood,
August 13, 2002;
100(5):
1611 - 1618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yamaguchi, T. Ariga, M. Yamada, D. L. Nelson, R. Kobayashi, C. Kobayashi, Y. Noguchi, Y. Ito, K. Katamura, Y. Nagatoshi, et al.
Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression
Blood,
July 30, 2002;
100(4):
1208 - 1214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Bunin, M. Carston, D. Wall, R. Adams, J. Casper, N. Kamani, R. King, and the National Marrow Donor Program Working Group
Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission
Blood,
May 1, 2002;
99(9):
3151 - 3157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Talvensaari, E. Clave, C. Douay, C. Rabian, L. Garderet, M. Busson, F. Garnier, D. Douek, E. Gluckman, D. Charron, et al.
A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation
Blood,
February 15, 2002;
99(4):
1458 - 1464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
